As of this week, three new options are available for generic Sunovion Pharmaceuticals Inc’s Lunesta (eszopiclone), a pharmacological treatment for insomnia.

Pittsburgh-based Mylan Inc launched Eszopiclone Tablets 1 mg, 2 mg, and 3 mg. Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for this product.

Jerusalem-based Teva Pharmaceutical Industries Ltd launched on April 15 a generic equivalent to Lunesta, 1, 2, and 3 mg, in the United States.

Hyderabad, India-based Dr. Reddy’s Laboratories launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg, and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market. Dr. Reddy’s received approval by the FDA.